Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 28

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 28
---
.
Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult,
time-consuming or costly and increase demand on our systems and resources. The Exchange Act requires that we file an annual report on
Form 20-F. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal control over financial
reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting
to meet this standard, significant resources and management oversight are required. As a result, management’s attention may be diverted
from other business concerns, which could adversely affect our business and results of operations.

We could become subject to the auditor attestation
requirement under the Sarbanes-Oxley Act even if we have little or no revenue, thus imposing significant cost and administrative burden
on us.

We currently qualify as an
“emerging growth company” and, as a result, are exempt from the auditor attestation requirement under Section 404 of the Sarbanes-Oxley
Act of 2002 in the assessment of internal controls over financial reporting. We expect to remain an emerging growth company until the
earlier of the last day of our fiscal year following the fifth anniversary of the completion of our first public offering in the United
States or, as of the last business day of our most recently completed second fiscal quarter, our aggregate worldwide market value of the
voting and non-voting common equity held by our non-affiliates is US$700 million or more. Once we cease to be an emerging growth company
and the aggregate worldwide market value of our voting equity held by non-affiliates exceeds US$75 million as of our most recently completed
second fiscal quarter, then we will be subject to the auditor attestation requirement in the assessment of the internal controls over
financial reporting.

While the U. S.
Securities and Exchange Commission (“ SEC”) has acknowledged the significant cost of the auditor attestation requirement
for small companies and provided an exemption for U. S. “smaller reporting companies” with less than US$100 million in
revenue, the SEC has decided not to similarly exempt foreign private issuers (such as Radiopharm) unless they comply with the
reporting requirements for U. S. companies, including presenting financial statements in accordance with U. S. generally accepted
accounting principles. Given the significant cost and administrative burden resulting from inconsistent reporting obligations under
the rules